Skip to main content
Go Back to System Level
Medical professionals reviewing screenings on two computer monitors

University of Maryland St. Joseph Medical Center's (UM SJMC) Cancer Institute is an active partner in advancing the understanding and treatment of cancer through clinical trials and research studies of people who have cancer. The goal of these studies is to find better ways to treat, diagnose and prevent cancer so that people can live better and longer.

Clinical trials are the engine of cancer research and can represent a patient's best chance for effective therapy. The clinical trials offered at UM St. Joseph Medical Center include preventive, treatment and observational research studies. They are based on nationally approved standards of cancer care and are designed to research how we can best improve our patients' cancer outcomes.

Patients have access to national, investigator-initiated and industry-sponsored clinical trials. The UM SJMC research team can help determine if a treatment option is right for a particular patient. As with all clinical trials, patients who enroll must meet specific criteria. Clinical trials currently in process at UM SJMC's Cancer Institute are below.

"There are many great reasons to be part of a clinical trial," says Kimberly Schlesinger, MD, medical director of the Cancer Institute at UM St. Joseph Medical Center. "If you think a clinical trial may be right for you, talk to your doctor to learn more."

Breast Cancer

  • S1418/BR006:
    A randomized phase III trial to evaluate the efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with ≥ 1 cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy.
  • A011401:
    A randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
  • A011202:
    A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (CTI-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.
  • A011502:
    The ABC Trial: A randomized phase III double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for HER2-negative breast cancer.
  • NRG-BR004:
    A randomized, double-blind, phase III trial of paclitaxel/trastuzumab/pertuzumab with atezolizumab or placebo in first-line HER2-positive metastatic breast cancer.
  • A211505:
    Phase III randomized trial of hypofractionated post-mastectomy radiation with breast reconstruction.

Renal Cancer 

  • A031505:
    Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (ambassador) versus observation.

    image of someone holding a vile that is labeled platelet count

All Cancers

  • A221602:
    A phase III randomized, double-blind, placebo-controlled trial: olanzapine with or without fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). 

Radiation Oncology

  • NRG CC003:
    Testing whether avoiding the hippocampus during whole-brain radiation therapy prevents cognitive side effects in patients with small cell lung cancer.

Registry

  • PROMPT:
    Prospective registry of multiplex testing, a research registry for people who have had a newer form of genetic testing, called multi-gene panels.

For more information about clinical trials at UM St. Joseph Medical Center, please call 410-427-2571.

In This Section: